RRM2 and neoplasm: Several nonspecific inhibitors of ribonucleotide reductase are in fact already in clinical use as chemotherapeutic agents, and more recently, an antisense agent targeting RRM2 has shown potent antitumour activity against a variety of tumours (Lee et al, 2003).